Compare REKR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REKR | BNR |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.7M | 94.4M |
| IPO Year | 2017 | 2019 |
| Metric | REKR | BNR |
|---|---|---|
| Price | $0.68 | $10.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 5.0K |
| Earning Date | 05-13-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,234,000.00 | N/A |
| Revenue This Year | $12.51 | $111.65 |
| Revenue Next Year | $23.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $6.66 |
| 52 Week High | $3.42 | $41.72 |
| Indicator | REKR | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 59.56 |
| Support Level | $0.60 | $8.69 |
| Resistance Level | $0.74 | $12.89 |
| Average True Range (ATR) | 0.04 | 0.41 |
| MACD | 0.01 | 0.19 |
| Stochastic Oscillator | 77.49 | 73.60 |
Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.